^
Association details:
| Biomarker: | ETV6 mutation |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY-DIAGNOSED PRIMARY CNS LYMPHOMA
Published date:
06/09/2023
Excerpt:
Multivariate Cox proportional hazard analysis demonstrated a significant 3.24-fold increased risk of progression with 6p CN-LOH/homozygous deletion or BTG1/ETV6 mutations….We identify CN-LOH and homozygous deletions involving the HLA region at 6p21 as well as BTG1 and ETV6 mutations as candidate genomic biomarkers that correlate with accelerated disease progression with MTR-based chemotherapy in PCNSL.
Secondary therapy:
temozolomide + methotrexate
DOI:
10.1002/hon.3163_14
